Several items stood out today when Lilly (NYSE: LLY) released fourth quarter and full year results so let’s get right to it;
1. Diabetes is the king of the castle but uneasy is the man who wears the crown.
There is no question that the strategy the company embarked on years ago is paying big dividends today. One number that jumped out today was sales for their once-weekly GLP-1 Trulicity which reached full year sales of over $2 billion.
However, as well as diabetes is doing the company is facing several challenges. As the company . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.